David Tonnelet
David Tonnelet is an expert in Hematology at Centre Henri Becquerel (France). David Tonnelet has authored 54 publications, the most recent in 2026, and is an investigator in 3 clinical trials, 3 of them ongoing. SLR score: 172 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Nuclear Medicine - Oncology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2017 - 2026
Number : 54
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study. PMID 42387196 — single photon emission computed tomography computed tomography, neoplasms, prostate, positron emission tomography computed tomography, neoplasm metastasis, tomography, emission-computed, single-photon, prostatic neoplasms, therapeutics | EJNMMI Res | 2026 | 1 |
| GMP-compliant automated synthesis and quality control of [ 177Lu]Lu-PSMA-I&T using the GAIA/LUNA Elysia-Raytest module for the treatment of metastatic castration-resistant prostate cancer. PMID 42154134 — quality control, neoplasms, prostate, prostatic neoplasms, castration, therapeutics | EJNMMI Radiopharm Chem | 2026 | 0 |
| Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma. PMID 42118857 — cells, lymphoma, b-cell, lymphoma, neoplasms, positron emission tomography computed tomography, tumor burden, risk factors, therapeutics, b-lymphocytes | Blood Adv | 2026 | 0 |
| Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study. PMID 41979332 — cells, circulating tumor dna, lymphoma, b-cell, lymphoma, neoplasms, predictive value of tests, therapeutics, dna, b-lymphocytes | Blood Adv | 2026 | 0 |
| Clinical value of per-treatment whole-body single-time-point automated dosimetry for [ 177Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer. PMID 41792565 — blood, single photon emission computed tomography computed tomography, neoplasms, prostate, prostatic neoplasms, castration, therapeutics | Eur J Nucl Med Mol Imaging | 2026 | 0 |
Clinical Studies 3
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Standard of Care 177Lu PSMA 617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6 Poor Responders) NCT06496581 — radiotherapy, safety, genital diseases, male, docetaxel, prednisone, neoplasms, prostate, hormones, prostatic diseases, prostatic neoplasms, therapeutics, genital diseases, male | Phase 3 | Recruiting | 2024 |
| A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide Doxorubicin Vincristine and Prednisone (CHOP) in Circulating Tumor (ct)DNA High Risk Patients With Untreated Diffuse Large B Cell Lymphoma NCT04980222 — cytokines, cells, body surface area, prednisolone, safety, prednisone, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, cyclophosphamide, doxorubicin, neoplasms, cytokine release syndrome, rituximab, vincristine, therapeutics, b-lymphocytes | Phase 2 | Active not recruiting | 2022 |
| Assessment of Retreatment With Lutathera in Patients With New Progression of Intestinal Well differenciated NET NCT04954820 — neoplasms, disease progression, retreatment, neuroendocrine tumors, therapeutics | Phase 2 | Recruiting | 2021 |
LeadR Networks
Main global connection map